Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832335 | 0.75 | ALDH1A1 (0.41) | OPRM1OPRL1MEN1KMT2ACYP2C9 | |
| SCHEMBL3021766 | 0.73 | MEN1 (0.57) | OPRM1OPRL1CXCR3MEN1KMT2A | |
| SCHEMBL11461558 | 0.72 | AKR1C1 (0.39) | OPRM1OPRL1MEN1KMT2ACYP2C9 | |
| SCHEMBL15037442 | 0.70 | OPRM1 (0.45) | OPRM1OPRL1CXCR3MEN1KMT2A | |
| SCHEMBL3017563 | 0.70 | OPRM1 (0.42) | OPRM1OPRL1CXCR3MEN1KMT2A | |
| SCHEMBL3017592 | 0.70 | ALDH1A1 (0.44) | OPRM1MEN1KMT2ACYP2C9GRIN1 | |
| SCHEMBL3712955 | 0.69 | MAPT (0.32) | MEN1KMT2ACRBNCYP1A2POLB | |
| SCHEMBL3706115 | 0.69 | KDM1A (0.30) | MEN1KMT2ACRBNCYP1A2POLB | |
| SCHEMBL3709972 | 0.67 | MAOB (0.55) | OPRM1OPRL1CXCR3MEN1KMT2A | |
| SCHEMBL7897277 | 0.67 | OPRM1 (0.39) | OPRM1OPRL1CXCR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| CN-119546604-A | Pyrido [3,2-D ] pyrimidines as HPK1 inhibitors | 默克专利有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4507789-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023201185-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| EP-3258929-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10351558-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180022747-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022747-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3258929-A1 | FACTOR IXa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016133793-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133793-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | WO | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022747-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | OPRM1 3598/4885OPRL1 3884/4885CXCR3 877/4885 |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, PPIP5K2, IP6K1 | OPRM1 4236/4885OPRL1 3919/4885CXCR3 2169/4885 |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | OPRM1 67/4885OPRL1 97/4885CXCR3 3635/4885 |
| US-10351558-B2 | Factor IXa inhibitors | F9, TFPI, F12 | OPRM1 3598/4885OPRL1 3884/4885CXCR3 877/4885 |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | OPRM1 67/4885OPRL1 97/4885CXCR3 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.